Anti-inflammatory aspects of Filgrastim and impact on IL-2 release.
G-CSF has immunomodulatory effects of neutrophilic granulocytes and monocytes/macrophages. Two studies were done: one in normal volunteers and the other in HIV-infected patients plus their respective control donors to evaluate the effect of Filgrastim on cytokine responses. Filgrastim treatment of volunteers resulted in an anti-inflammatory cytokine response, when blood was stimulated ex vivo with the endotoxin lipopolysaccharide (LPS). Similarly, in the presence of Filgrastim in vitro, the LPS-inducible release of proinflammatory cytokines was attenuated. Blood from HIV-infected patients at advanced stages of disease showed reduced interleukin (IL)-2 formation in response to staphylococcal exotoxin B (SEB), which was restored in the presence of Filgrastim.
Hartung
T
T
University of Konstanz, Germany.
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines / Q000097:blood*; D005083:Exfoliatins / Q000633:toxicity; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000276:immunology / Q000494:pharmacology* / Q000627:therapeutic use*; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007376:Interleukin-2 / Q000097:blood*; D008070:Lipopolysaccharides / Q000633:toxicity; D008297:Male; D011994:Recombinant Proteins; D012016:Reference Values
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D005083:Exfoliatins; D007376:Interleukin-2; D008070:Lipopolysaccharides; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim